Clinical Research Advantage (CRA), the country’s largest wholly owned network of clinical trial sites, has further expanded its geographic and therapeutic reach by acquiring the late phase division of Comprehensive Clinical Development (CCD). This transaction will allow CRA to offer pharmaceutical sponsors and contract research organizations an across-the-board solution for their diverse clinical research needs.

Clinical Research Advantage includes 63 sites listed under “CRA” and “Radiant Research.” Both brands are known as leaders in Stage II-IV clinical trials. CRA focuses on on family practice and general medicine, while Radiant conducts multi-specialty and consumer trials. Comprehensive Clinical Development is a leader in psychiatric clinical trials, specifically in the areas of schizophrenia, bipolar disorder, depression, and Alzheimer’s disease. CCD has participated in the development of every major psychiatric drug that has been developed over the past 10 years, and it is recognized in the industry as a high quality researcher and successful enroller for psychiatric trials.

“By adding Comprehensive Clinical Development to the CRA family of trial sites we are able to increase our capabilities to meet the needs of the growing pharmaceutical marketplace,” said Mark S. Hanley, Chief Executive Officer of CRA. “We are excited about this partnership and the opportunity to move into new therapeutic areas of clinical research. CCD has an impressive track record in psychiatric trials, and we see it as an ideal partner as we continue to expand our operations.”

Based in Miramar, Fla., CCD was founded in 1998. The company operates four independent sites in Atlanta, Ga., Cerritos, Calif., Holliswood, N.Y., and Washington, D.C. The combined companies will continue to function under the names Clinical Research Advantage and Comprehensive Clinical Development, but will be looking to integrate and streamline their operations where appropriate.